About Us

OUR MISSION IS TO DRAMATICALLY IMPROVE THE LIVES OF PATIENTS BY DEVELOPING BREAKTHROUGH NON-OPIOID PAIN THERAPEUTICS THAT ADDRESS SIGNIFICANT UNMET MEDICAL NEEDS

The reduction in the use of opioids has been established as a high priority at every level of government and public health organization. Concentric Analgesics, Inc., a private, biopharmaceutical company, is focused on discovering and developing novel non-opioid therapeutics for the management of acute and chronic pain.

Founded in 2014 and based in San Francisco, California, Concentric has a portfolio of proprietary products designed to provide long-lasting, selective pain relief after a single local administration. We have active development programs for three important and underserved indications: management of postsurgical pain, chronic osteoarthritis pain, and refractory pain.

The lead molecule for each indication is a prodrug therapeutic that rapidly converts to capsaicin, a potent TRPV-1 agonist. Capsaicin selectively desensitizes pain-conducting nerve fibers without producing sensory numbness or motor weakness.

Vocacapsaicin (CA-008), the company’s most advanced product candidate for postsurgical pain, is Phase-3 ready. It has received both Fast Track Designation (2017) and Breakthrough Therapy Designation (2018) from the FDA. Our therapeutic approach has the potential to be a game changer by harnessing the benefits of TRPV1 agonism to provide long-lasting pain relief, reduced opioid use and an excellent safety profile in a broad array of postsurgical pain settings.